SFI Strategic Partnership

Abstract

The overarching goals of the program are to:

• Capture and codify, in a timely fashion, previous successes of the collaboration; We aim to capture and codify an existing set of productive collaborations into a stable and efficient research platform. The outline of this platform has evolved over some years of specific smaller-scale collaborations. This platform, its skills, and methodologies, will then be adopted and integrated into Marigot's own research centre, currently under development.
• Leverage UCDs' strength in particulate science and animal model research; CBNI has developed the most advanced approaches to complex particulate material definition and studying biological interactions available. SVM-UCD has an established record of mechanisticin vivoinvestigations that can support Marigot's own large scale animal studies. Together, these will establish a firm and reportable causal connection between specific materials, their properties, and the animal health endpoints.
• Learn from naturally occurring particle architectural paradigms to develop new particles; We propose to develop simplified particulate analogues (mimetics) of the most promising naturally occurring particulates and test them alongside other competitive particles.
• Use characterisation and particle control as a means to access higher added value markets; We propose to use our experience in regulatory matters to develop a reportable material description file that will support company efforts to access higher added value (for example pharma-linked) markets.
• Capture radically new insights, and advance towards hypothesis-driven research; We propose to evolve the research so that, in future, such investigations into complex particulates will be hypothesis-driven

MARIGOT LTD.
Marigot Ltd. was established in 1993 by Les Auchincloss, previously founder and major shareholder of Biocon Limited until the acquisition by the Quest Division of Unilever in 1989.
Operating under a system that fosters an entrepreneurial approach, the core business involves the identification and development of naturally derived ingredients for the enhancement of Human, Animal and Plant Health. During the last 24 years, Marigot Ltd has operated with a unique appreciation and mindful understanding of its raw material. The company has worked tirelessly with relevant stakeholders and external parties, ensuring that material is harvested sustainably and with maximum sensitivity to the environment. From this backdrop, Marigot has created and developed the market for this unique marine multi-mineral, covering both the animal health and human food and nutrition sectors. Today, its products are sold in over 40 countries through exclusively appointed distribution partners.

A unique facet of Marigot’s commitment to its raw material has been its dedication to top-tier peer reviewed research. The company invests as much as 5-10% of sales turnover annually in research based programs, to further understand the efficacy of this unique, natural mineral source. This approach coupled with processing technology, optimised inclusion systems and application development has allowed Aquamin to be successfully included in a wide range of human foods and dietary supplement formulations. The company can count some of the world’s leading blue-chip feed and food producers as its valued customers.

About Aquamin SeaweedMineral Complex Marigot supply the Aquamin branded range of marine minerals derived from two sources: Marine Plant (Seaweed) & Seawater. The products are used to add nutritional value to a wide range of food & nutraceutical applications. 
Aquamin is a natural, marine-sourced multi-mineral, which is derived from the cytoskeleton of the red algal Lithothamnion spp. Over the course of the aquatic plant's life, minerals are accumulated from the seawater, and stored as carbonate salts in the plant. 74 components have been identified in total.
Other than washing and milling, Aquamin is unaltered from the raw material and as such represents a natural multi-mineral material that is suitable for many food and supplement applications.
Although numerous anecdotal reports of health benefits associated with consumption of Aquamin existed, no objective research was carried out until Marigot Ltd. undertook to understand exactly how Aquamin could impact human health. Over 20 years, Marigot Ltd. have accumulated a large and growing body of research evaluating Aquamin in work spanning in vitro assays, numerous animal models and human trials. This portfolio of research has been conducted independently, and largely at academic institutions across the world, - by investigators that are renowned in their respective fields. All researchers are encouraged to publish their results on Aquamin in peer-reviewed scientific journals. As such, this research can be accessed by all and has withstood critique from peers in the relevant field(s).
Aquamin has been demonstrated to have superior bioavailability than other, commonly available calcium sources and has beneficial effects on bone, inflammation, specifically osteoarthritic conditions, digestive health, and cardiovascular health.

Images